)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Niagen Bioscience
Niagen Bioscience (NAGE) investor relations material
Niagen Bioscience Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 2026 net sales fell 20% YoY to $27.192M; operating loss was $1.587M and net loss was $1.173M, while Adjusted EBITDA remained positive at $0.455M.
Cash ended the quarter at $69.509M with no borrowings; Q3 operating cash flow was $2.6M.
2026 was framed as an investment year, with launches and distribution expansion supporting growth initiatives for 2027 and beyond.
Financial highlights
Q3 gross profit was $17.105M versus $21.928M a year earlier; gross margin was 62.9% versus 64.5%.
Q3 operating expenses rose to $18.7M from $17.7M, led by G&A; Q3 G&A was $8.2M, primarily reflecting higher legal fees.
Nine-month net sales were $88.451M versus $95.584M; net income was $6.108M versus $13.250M, including a $4.8M divestiture gain in 2026.
Nine-month operating cash flow was $4.203M versus $12.8M in 2025; cash rose to $69.509M from $64.8M at year-end 2025.
Outlook and guidance
Q4 revenue is expected to improve sequentially from Q3; FY2026 e-commerce growth is forecast at ~5%, with the remainder of consumer business expected to offset it.
FY2026 direct website revenue growth of 15%–20% is expected; Niagen Plus and skincare are expected to contribute beginning in 2027.
Ingredient revenue is expected below prior year, mainly due to lower key-partner volumes; commercialization of a lower-cost NR salt is expected in early 2027, with COGS benefits thereafter.
2026 investment priorities include brand, distribution, products, research, NB4168 and operational expansion; operating expenses are expected to increase.
NB4168 IND-enabling studies are expected to finish in early 2027, with first-in-human studies planned for 2027, subject to development completion and regulatory clearance.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Niagen Bioscience
- A profitable NAD+ platform is funding expansion into IVs, skincare, and therapeutics.NAGE
Corporate presentation - Rare-disease drug ambitions extend a profitable NAD platform into new channels.NAGELD Micro 20th Annual Main Event Conference
- Strong growth, innovation, and a leading NAD drug pipeline position the company for future success.NAGE17th Annual Midwest IDEAS Conference
- Strong NAD+ supplement sales, new skincare launches, and robust cash flow support biotech growth.NAGECanaccord Genuity's 46th Annual Growth Conference
- Q2 2026 delivered $29.8M sales, $1M net income, and major telehealth and pharma launches.NAGEQ2 2026
- NB4168 advances NAD science into pharmaceuticals, targeting rare diseases with strong safety data.NAGEFireside chat
- Advancing NB4168 for rare genetic diseases with strong clinical data and premium market potential.NAGECorporate presentation
- Patented NAD+ products, strong clinical data, and expanding verticals drive robust growth.NAGECorporate presentation
- Record revenue, profitability, and cash flow set the stage for double-digit growth in 2025.NAGEQ4 2024
Next Niagen Bioscience earnings date
18th Annual Southwest IDEAS Conference19 Nov, 2026
Niagen Bioscience
Next Niagen Bioscience earnings date
18th Annual Southwest IDEAS Conference19 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ChromaDex Corporation is a biosciences company that develops and markets ingredients and consumer products based on nicotinamide riboside and other proprietary compounds. Its product portfolio supports healthy aging and cellular health, distributed through e-commerce and retail. The company is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.